BioCentury | Mar 5, 2007
Emerging Company Profile

ApopLogic: Finding cell death drivers

...traditionally been developed for autoimmune and inflammatory diseases. ApopLogic was founded to develop and commercialize Fasaret...
...licensed the product to Novartis AG (NVS; SWX:NOVN, Basel, Switzerland) to treat transplant rejection. When Fasaret...
Items per page:
1 - 1 of 1